Amarin Corp Plcuk (AMRN) Other Accumulated Expenses (2010 - 2025)
Amarin Corp Plcuk (AMRN) posted quarterly Other Accumulated Expenses of $18.3 million for Q4 2025, up 4.52% YoY from $17.5 million in Q4 2024, and up 4.52% sequentially from $17.5 million in Q4 2024.
Amarin Corp Plcuk (AMRN) Other Accumulated Expenses (2010 - 2025) Analysis & Trends
Amarin Corp Plcuk has disclosed Other Accumulated Expenses across 16 years of filings, most recently posting $18.3 million for Q4 2025.
- In Q4 2025, Other Accumulated Expenses rose 4.52% year-over-year to $18.3 million; the TTM figure through Dec 2025 stood at $18.3 million (up 4.52% YoY), while the FY2025 annual figure was $18.3 million, up 4.52% from the prior year.
- Other Accumulated Expenses climbed to $18.3 million in Q4 2025, from $17.5 million in the prior quarter.
- Over the last five years, Other Accumulated Expenses for AMRN reached as high as $45.6 million in Q4 2021 and fell as low as $17.5 million in Q4 2024.
- The 5-year median for Other Accumulated Expenses is $23.0 million (2023), against an average of $28.0 million.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses surged 58.42% — and 2023, when it tumbled 35.41%.
- A 5-year view of Other Accumulated Expenses shows it stood at $45.6 million in 2021, then fell by 21.84% to $35.6 million in 2022, then plunged by 35.41% to $23.0 million in 2023, then decreased by 23.79% to $17.5 million in 2024, then advanced by 4.52% to $18.3 million in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $18.3 million, $17.5 million, and $23.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.34 Mn |
| Dec 31, 2024 | 17.55 Mn |
| Dec 31, 2023 | 23.02 Mn |
| Dec 31, 2022 | 35.64 Mn |
| Dec 31, 2021 | 45.60 Mn |
| Dec 31, 2020 | 28.79 Mn |
| Dec 31, 2019 | 16.59 Mn |
| Dec 31, 2018 | 7.71 Mn |
| Dec 31, 2017 | 5.16 Mn |
| Dec 31, 2016 | 5.80 Mn |
| Dec 31, 2015 | 4.28 Mn |
| Dec 31, 2014 | 2.25 Mn |
| Dec 31, 2013 | 3.34 Mn |
| Dec 31, 2012 | 3.15 Mn |
| Dec 31, 2011 | 1.78 Mn |
| Dec 31, 2010 | 572,000.00 |